A potential rival for Allergan Plc's blockbuster Botox has passed a late-stage study, putting drug developer Revance Therapeutics Inc on course to file for U.S. marketing approval next year.
Revance Therapeutics' Botox rival succeeds in late-stage trial
![Revance Therapeutics' Botox rival succeeds in late-stage trial]()
Reviewed by jenisht
on
December 05, 2018
Rating:
No comments: